These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 12211043)

  • 1. DNA-based immunotherapy: potential for treatment of chronic viral hepatitis?
    Beckebaum S; Cicinnati VR; Gerken G
    Rev Med Virol; 2002; 12(5):297-319. PubMed ID: 12211043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a heterologous, multigenotype vaccine against hepatitis C virus infection.
    Encke J; Radunz W; Eisenbach C; Geib J; Gehrke S; Pfaff E; Stremmel W
    Eur J Clin Invest; 2007 May; 37(5):396-406. PubMed ID: 17461986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines and immunotherapies against hepatitis B and hepatitis C viruses.
    Inchauspé G; Michel ML
    J Viral Hepat; 2007 Nov; 14 Suppl 1():97-103. PubMed ID: 17958650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic vaccination in chronic hepatitis B virus carriers.
    Pol S; Michel ML
    Expert Rev Vaccines; 2006 Oct; 5(5):707-16. PubMed ID: 17181443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current developments in viral DNA vaccines: shall they solve the unsolved?
    Rajcáni J; Mosko T; Rezuchová I
    Rev Med Virol; 2005; 15(5):303-25. PubMed ID: 15906276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic vaccination in chronic hepatitis B: preclinical studies in the woodchuck model.
    Roggendorf M; Schulte I; Xu Y; Lu M
    J Viral Hepat; 2007 Nov; 14 Suppl 1():51-7. PubMed ID: 17958643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CpG immuno-stimulatory motifs enhance humoral immune responses against hepatitis C virus core protein after DNA-based immunization.
    Encke J; zu Putlitz J; Stremmel W; Wands JR
    Arch Virol; 2003 Mar; 148(3):435-48. PubMed ID: 12607097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DNA vaccines for prophylactic or therapeutic immunization against hepatitis B virus.
    Davis HL
    Mt Sinai J Med; 1999 Mar; 66(2):84-90. PubMed ID: 10100411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ability of Hepatitis B surface antigen DNA vaccine to elicit cell-mediated immune responses, but not antibody responses, was affected by the deglysosylation of S antigen.
    Xing Y; Huang Z; Lin Y; Li J; Chou TH; Lu S; Wang S
    Vaccine; 2008 Sep; 26(40):5145-52. PubMed ID: 18462847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic vaccines and immune-based therapies for the treatment of chronic hepatitis B: perspectives and challenges.
    Michel ML; Deng Q; Mancini-Bourgine M
    J Hepatol; 2011 Jun; 54(6):1286-96. PubMed ID: 21238516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel HBV DNA vaccine based on T cell epitopes and its potential therapeutic effect in HBV transgenic mice.
    Li X; Yang X; Jiang Y; Liu J
    Int Immunol; 2005 Oct; 17(10):1293-302. PubMed ID: 16113237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers.
    Mancini-Bourgine M; Fontaine H; Bréchot C; Pol S; Michel ML
    Vaccine; 2006 May; 24(21):4482-9. PubMed ID: 16310901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune responses to recombinant Mycobacterium smegmatis expressing fused core protein and preS1 peptide of hepatitis B virus in mice.
    Yue Q; Hu X; Yin W; Xu X; Wei S; Lei Y; Lü X; Yang J; Su M; Xu Z; Hao X
    J Virol Methods; 2007 Apr; 141(1):41-8. PubMed ID: 17197041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune tolerance against HBV can be overcome in HBV transgenic mice by immunization with dendritic cells pulsed by HBVsvp.
    Farag MM; Tedjokusumo R; Flechtenmacher C; Asen T; Stremmel W; Müller M; Protzer U; Weigand K
    Vaccine; 2012 Sep; 30(42):6034-9. PubMed ID: 22867720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic and therapeutic vaccination with dendritic cells against hepatitis C virus infection.
    Encke J; Findeklee J; Geib J; Pfaff E; Stremmel W
    Clin Exp Immunol; 2005 Nov; 142(2):362-9. PubMed ID: 16232225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective functional deficit in dendritic cell--T cell interaction is a crucial mechanism in chronic hepatitis B virus infection.
    Zheng BJ; Zhou J; Qu D; Siu KL; Lam TW; Lo HY; Lee SS; Wen YM
    J Viral Hepat; 2004 May; 11(3):217-24. PubMed ID: 15117323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The woodchuck: a model for therapeutic vaccination against hepadnaviral infection.
    Roggendorf M; Yang D; Lu M
    Pathol Biol (Paris); 2010 Aug; 58(4):308-14. PubMed ID: 20646874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production and efficacy of a dendritic cell-based therapeutic vaccine for murine chronic hepatitis B virus carrierer.
    Akbar SM; Furukawa S; Hasebe A; Horiike N; Michitaka K; Onji M
    Int J Mol Med; 2004 Aug; 14(2):295-9. PubMed ID: 15254781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine-dependent anti-viral role of CD4-positive T cells in therapeutic vaccination against chronic hepatitis B viral infection.
    Ren F; Hino K; Yamaguchi Y; Funatsuki K; Hayashi A; Ishiko H; Furutani M; Yamasaki T; Korenaga K; Yamashita S; Konishi T; Okita K
    J Med Virol; 2003 Nov; 71(3):376-84. PubMed ID: 12966542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HCV-NS3 Th1 minigene vaccine based on invariant chain CLIP genetic substitution enhances CD4(+) Th1 cell responses in vivo.
    Gao M; Wang HP; Wang YN; Zhou Y; Wang QL
    Vaccine; 2006 Jun; 24(26):5491-7. PubMed ID: 16725235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.